The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis

Table 2

Multivariate analysis of composite outcome in patients with AAV.

	Univariate		Multivariate		Multivariate^†
	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
Plasma suPAR levels (per 500 pg/mL increase)	1.07 (1.03-1.12)	0.002	1.05 (1.01-1.11)	0.043	1.02 (0.96-1.08)	0.563
Age (year)^§	1.04 (1.01-1.08)	0.017	1.03 (0.99-1.07)	0.128	1.05 (1.01-1.10)	0.025
Gender (male vs. female)	1.02 (0.48-2.19)	0.957	0.98 (0.46-2.11)	0.961	0.74 (0.30-1.83)	0.515
Initial serum creatinine (per mg/dL)	1.17 (1.06-1.30)	0.003	—	—	1.22 (1.06-1.41)	0.006
Urinary protein (per g/24 h)	0.93 (0.66-1.30)	0.699	—	—	1.03 (0.71-1.49)	0.879

Adjusted for age, gender; ^†adjusted for age, gender, initial serum creatinine, and urinary protein; ^§per 1 unit increase. Abbreviations: AAV: antineutrophil cytoplasmic antibody-associated vasculitis; HR: hazard ratio; CI: confidence interval.